Lv7
3390 积分 2021-06-03 加入
Treatment experience in patients (pts) with advanced ovarian cancer (AOC) who received PARP inhibitor (PARPi) as the first-line (1L) maintenance therapy (MTx) in the real world by homologous recombination deficiency (HRD)/BRCA status
5天前
已关闭
Autologous CD19/BCMA CAR-T cell therapy for myasthenia gravis: Advancing care for those with severe disease
18天前
已完结
Autologous CD19 CAR T-cell therapy for pediatric and adult systemic lupus erythematosus: a phase 1/2 trial
18天前
已完结
One woman, three autoimmune diseases: CAR-T therapy vanquishes ultra-rare disease trio
18天前
已关闭
Multimodal imaging reveals a lysosomal drug reservoir that drives heterogeneous distribution of PARP inhibitors
26天前
已完结
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
1个月前
已完结
Engineering in vivo CAR-T cells
1个月前
已完结
Enhancing CAR-NK cell efficacy in solid tumours
1个月前
已完结
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
1个月前
已完结
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
1个月前
已完结
皖公网安备34019202002308
